| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | 0 |
Sells | $1,362,930 | 22 | 100 |
| Zak Lourie S. | Chief Financial Officer | 0 | $0 | 1 | $4,921 | $-4,921 |
| Smalling Ralph | Head of Regulatory | 0 | $0 | 2 | $9,550 | $-9,550 |
| Tyree James L | director | 0 | $0 | 2 | $13,010 | $-13,010 |
| Ryder Sean | General Counsel | 0 | $0 | 1 | $13,067 | $-13,067 |
| Yu Yong | VP, Clinical Trial Operations | 0 | $0 | 1 | $16,291 | $-16,291 |
| Cappello Joseph | VP, Pharmaceutical Development | 0 | $0 | 2 | $28,574 | $-28,574 |
| Zindrick Thomas | President and CEO | 0 | $0 | 2 | $64,928 | $-64,928 |
| Szalay Aladar | 10 percent owner | 0 | $0 | 11 | $1.21M | $-1.21M |
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Over the last 12 months, insiders at Genelux Corporation have bought $0 and sold $1.36M worth of Genelux Corporation stock.
On average, over the past 5 years, insiders at Genelux Corporation have bought $536,625 and sold $8.16M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,500 shares for transaction amount of $10,000 was made by Yu Yong (VP, Clinical Trial Operations) on 2024‑05‑29.
| 2025-05-12 | Sale | Zindrick Thomas | President and CEO | 10,764 0.03% | $2.92 | $31,431 | -0.18% | |
| 2025-05-12 | Sale | Cappello Joseph | VP, Pharmaceutical Development | 4,737 0.0132% | $2.92 | $13,832 | -0.18% | |
| 2025-05-12 | Sale | Yu Yong | VP, Clinical Trial Operations | 5,579 0.0155% | $2.92 | $16,291 | -0.18% | |
| 2025-05-12 | Sale | Ryder Sean | General Counsel | 4,475 0.0125% | $2.92 | $13,067 | -0.18% | |
| 2025-05-12 | Sale | Smalling Ralph | Head of Regulatory | 1,259 0.0035% | $2.92 | $3,676 | -0.18% | |
| 2024-12-30 | Sale | Tyree James L | director | 3,460 0.0099% | $2.46 | $8,512 | +21.88% | |
| 2024-12-16 | Sale | Zak Lourie S. | Chief Financial Officer | 2,103 0.0061% | $2.34 | $4,921 | +22.46% | |
| 2024-12-16 | Sale | Zindrick Thomas | President and CEO | 14,315 0.0416% | $2.34 | $33,497 | +22.46% | |
| 2024-12-16 | Sale | Smalling Ralph | Head of Regulatory | 2,510 0.0073% | $2.34 | $5,873 | +22.46% | |
| 2024-12-16 | Sale | Cappello Joseph | VP, Pharmaceutical Development | 6,300 0.0183% | $2.34 | $14,742 | +22.46% | |
| 2024-09-13 | Sale | Szalay Aladar | 10 percent owner | 33,080 0.1008% | $2.57 | $84,946 | +11.27% | |
| 2024-09-12 | Sale | Szalay Aladar | 10 percent owner | 31,777 0.0941% | $2.73 | $86,732 | +1.50% | |
| 2024-09-11 | Sale | Szalay Aladar | 10 percent owner | 31,376 0.0949% | $2.62 | $82,227 | +4.23% | |
| 2024-09-11 | Sale | Tyree James L | director | 1,730 0.0052% | $2.60 | $4,499 | +4.23% | |
| 2024-09-10 | Sale | Szalay Aladar | 10 percent owner | 20,384 0.059% | $2.51 | $51,182 | +7.97% | |
| 2024-09-09 | Sale | Szalay Aladar | 10 percent owner | 23,383 0.0678% | $2.70 | $63,200 | +0.19% | |
| 2024-09-03 | Sale | Szalay Aladar | 10 percent owner | 42,818 0.1248% | $2.09 | $89,614 | +30.05% | |
| 2024-08-30 | Sale | Szalay Aladar | 10 percent owner | 142,589 0.4134% | $2.17 | $309,846 | +24.42% | |
| 2024-08-29 | Sale | Szalay Aladar | 10 percent owner | 107,045 0.31% | $1.98 | $211,960 | +36.36% | |
| 2024-08-28 | Sale | Szalay Aladar | 10 percent owner | 15,918 0.0477% | $2.05 | $32,605 | +36.36% |
| Szalay Aladar | 10 percent owner | 599821 1.5896% | $2M | 0 | 42 | |
| Zindrick Thomas | President and CEO | 191447 0.5073% | $637,518.51 | 1 | 3 | <0.0001% |
| Cappello Joseph | VP, Pharmaceutical Development | 52266 0.1385% | $174,045.78 | 0 | 3 | |
| Yu Yong | VP, Clinical Trial Operations | 47640 0.1262% | $158,641.20 | 1 | 15 | <0.0001% |
| Ryder Sean | General Counsel | 47621 0.1262% | $158,577.93 | 1 | 4 | <0.0001% |
| Tyree James L | director | 45791 0.1213% | $152,484.03 | 1 | 3 | <0.0001% |
| Zak Lourie S. | Chief Financial Officer | 40802 0.1081% | $135,870.66 | 1 | 1 | <0.0001% |
| Smalling Ralph | Head of Regulatory | 34760 0.0921% | $115,750.80 | 1 | 3 | <0.0001% |
| Thomas John | director | 465960 1.2348% | $1.55M | 1 | 4 | <0.0001% |
| Jewett Caroline | Head of Quality | 16174 0.0429% | $53,859.42 | 0 | 2 | |
| Smither John W | director | 13170 0.0349% | $43,856.10 | 1 | 1 | <0.0001% |
| Mirabelli Mary | director | 12460 0.033% | $41,491.80 | 1 | 0 | <0.0001% |
| Samuelson Doug | Chief Financial Officer | 2303 0.0061% | $7,668.99 | 0 | 1 | |
| Zhang Qian | Associate VP, Research | 200 0.0005% | $666.00 | 1 | 0 | +278.21% |
$48,218,096 | 42 | 0.89% | $125.2M | |
$6,915,275 | 21 | -32.61% | $118.83M | |
$294,424,120 | 20 | 1.33% | $129.54M | |
$448,999,793 | 15 | -19.99% | $135.53M | |
$4,701,608 | 14 | -4.34% | $115.43M | |
$73,968,137 | 12 | -34.52% | $135.06M | |
Genelux Corporation (GNLX) | $1,073,250 | 10 | 19.46% | $125.66M |
$9,999,920 | 10 | -40.03% | $128.37M | |
$478,647 | 7 | 69.41% | $124.34M | |
$22,090,972 | 7 | -3.49% | $132.51M | |
$68,692,148 | 6 | -39.10% | $124.17M | |
$63,981 | 5 | -11.55% | $136.79M | |
$4,745,999 | 5 | -4.91% | $118.18M | |
$762,555 | 4 | -34.52% | $111.9M | |
$59,900 | 4 | -5.37% | $118.39M | |
$9,999,990 | 2 | 25.53% | $137.77M | |
$19,175,155 | 2 | 40.00% | $122.87M | |
$300,016 | 1 | -50.33% | $136.83M | |
$5,512,500 | 1 | -7.91% | $139.97M |
| Increased Positions | 48 | +84.21% | 3M | +56.97% |
| Decreased Positions | 20 | -35.09% | 362,146 | -7.41% |
| New Positions | 26 | New | 2M | New |
| Sold Out Positions | 10 | Sold Out | 247,154 | Sold Out |
| Total Postitions | 85 | +49.12% | 7M | +49.56% |
| Woodward Diversified Capital, Llc | $3,843.00 | 3.85% | 1.46M | +192,808 | +15.2% | 2025-03-31 |
| Vanguard Group Inc | $3,121.00 | 3.12% | 1.19M | +201,967 | +20.51% | 2024-12-31 |
| Blackrock, Inc. | $920.00 | 0.92% | 349,775 | +3,571 | +1.03% | 2025-03-31 |
| Geode Capital Management, Llc | $798.00 | 0.8% | 303,318 | -12,842 | -4.06% | 2024-12-31 |
| Bank Of America Corp /De/ | $571.00 | 0.57% | 217,106 | +325 | +0.15% | 2024-12-31 |
| Provident Wealth Management, Llc | $418.00 | 0.42% | 158,867 | 0 | 0% | 2025-03-31 |
| Marshall Wace, Llp | $410.00 | 0.41% | 156,058 | +52,958 | +51.37% | 2024-12-31 |
| Millennium Management Llc | $396.00 | 0.4% | 150,510 | -214,419 | -58.76% | 2024-12-31 |
| Lpl Financial Llc | $248.00 | 0.25% | 94,144 | +39,516 | +72.34% | 2024-12-31 |
| State Street Corp | $241.00 | 0.24% | 91,650 | +22,000 | +31.59% | 2024-12-31 |